HS Code:
Chemical contraceptive preparations based on hormones, other products of heading 2937, or spermicides (HS Code: 300660) include pharmaceutical products designed for birth control. These products encompass hormonal contraceptives such as birth control pills, patches, and injections, as well as spermicidal agents used to prevent pregnancy. This category is critical to global health initiatives, reproductive health programs, and family planning policies. Trade in this category is influenced by regulatory frameworks, public health policies, and cultural attitudes toward contraception.
Total Trade Volume
USD 6.2 billion
Data from 2022
Source
United Nations Comtrade Database
USD 1.1 billion
17.7% of total trade of total trade
Increasing
USD 900 million
14.5% of total trade of total trade
Stable
USD 750 million
12.1% of total trade of total trade
Increasing
USD 600 million
9.7% of total trade of total trade
Stable
USD 450 million
7.3% of total trade of total trade
Increasing
Average Rate
5.2% ad valorem
Highest Rate
12% (applied by certain developing countries)
Lowest Rate
0% (under free trade agreements and WTO commitments)
Rising demand for hormonal contraceptives in developing regions
Increased export opportunities for manufacturers in Europe and India, supported by global health initiatives like UNFPA programs.
2021-2022
Shift toward long-acting reversible contraceptives (LARCs)
Growing trade in hormonal implants and intrauterine devices, impacting traditional pill-based contraceptive exports.
2020-2022
Increased focus on generic and affordable contraceptives
Boost in exports from countries like India due to cost-effective production and high demand in low-income countries.
2019-2022
The European Union introduced updated guidelines for the approval and distribution of hormonal contraceptives to streamline market access across member states.
March 2023
Expected to reduce trade barriers within the EU, boosting intra-regional trade and benefiting major exporters like Germany and Belgium.
The United States renewed funding commitments for international family planning programs, increasing procurement of contraceptives for aid distribution.
January 2023
Significant rise in demand for contraceptive supplies from key exporters, particularly for shipments to Sub-Saharan Africa and South Asia.
Indian pharmaceutical companies received support from government initiatives to expand generic contraceptive production and exports under the 'Make in India' campaign.
September 2022
Strengthened India's position as a leading supplier to developing markets, increasing competition with European exporters.